PhD in Therapeutic Potential of Repositioned Nanoformulations of Psychiatric Medications in Glioblastoma Kingston University in United Kingdom

Kingston University invites applications for a PhD project exploring the therapeutic potential of repositioned nanoformulations of psychiatric medications in glioblastoma (GBM), the most aggressive primary brain tumour. GBM presents significant clinical challenges due to its rapid progression, late diagnosis, and poor prognosis, with a 10-year survival rate below 1%. Current treatments, including surgery and chemoradiation, offer limited survival benefits, highlighting the urgent need for innovative therapies.

This project leverages drug repurposing strategies, focusing on psychiatric medications with inherent brain-targeting properties, to overcome the blood–brain barrier (BBB) and address treatment resistance in GBM. The research will systematically screen antidepressants, anxiolytics, stimulants, antipsychotics, and mood stabilisers for anticancer activity in both cancerous and healthy brain cell lines. A key aim is to elucidate the mechanisms of action of these compounds, particularly their effects on underexplored signalling pathways such as PI3K/Akt/mTOR, Ras/MAPK, Wnt/β-catenin, Notch, Hippo, and RSK2, which are implicated in GBM progression and therapeutic resistance.

The project will also develop and evaluate nanoformulations to enhance drug delivery across the BBB, potentially improving therapeutic efficacy. Collaborations with the University of Birmingham (proteomics) and The Institute of Cancer Research (genomics analysis) will provide access to advanced analytical platforms, broadening the research scope and impact. The anticipated outcomes include high-quality research publications and contributions to the development of novel GBM therapies.

Comprehensive training will be provided in cell and molecular biology, biochemistry, and a range of analytical techniques, including immunoblotting, microscopy, PCR, scratch assays, mass spectrometry, RNA sequencing, and flow cytometry. Applicants should possess a first or upper second class honours degree, with a master’s degree or equivalent research experience being essential. A background in relevant biological or biochemical sciences is highly desirable.

This project is part of the Graduate School studentships competition for October 2026 entry. Applicants should initially apply as 'self-funded'; successful candidates will have their funding status updated internally if awarded a studentship. For further details and to apply, visit the Kingston University Research Degrees portal.